Lilly Gemzar
Executive Summary
Gemcitabine/cisplatin shows similar survival and less toxicity than a methotrexate/vinblastine/adriamycin/cisplatin regimen in a Phase III bladder cancer study reported at ASCO. Median survival was 13.8 months in the Gemzar arm and 14.8 months in the MVAC arm. The incidences of neutropenic sepsis, neutropenic fever and mucositis were lower in the Gemzar arm. Anemia and thrombocytopenia occurred more frequently in the Gemzar arm, however. Lilly submitted an sNDA for advanced bladder cancer in the third quarter of 1999. Gemzar is currently indicated for the treatment of pancreatic cancer and in combination with cisplatin for non-small cell lung cancer
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth